BI 1584862
Alternative Names: BI-1584862Latest Information Update: 08 Dec 2023
At a glance
- Originator Boehringer Ingelheim
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 04 Dec 2023 Boehringer Ingelheim plans a phase I pharmacokinetics trial (In volunteers, In adults) (PO), in December 2023 (NCT06148948)
- 20 Sep 2023 Boehringer Ingelheim plans a phase I pharmacokinetics trial (In volunteers, In adults) (PO), in September 2023 (EudraCT2023-503542-31-00) (NCT06041438)
- 02 Sep 2022 Boehringer Ingelheim plans a phase I trial in Healthy volunteers in Germany in September 2022 (NCT05520827)